TABLE 1.
Antiviral activity of pibrentasvir in vitro
| HCV replicon or virus | Pibrentasvir EC50 (pM)c |
|---|---|
| HCV stable replicons in 0% human plasmaa | |
| GT1a H77 | 1.8 ± 0.86 |
| GT1b Con1 | 4.3 ± 1.7 |
| GT2a JFH-1 | 5.0 ± 0.60 |
| GT2ab | 2.3 ± 0.65 |
| GT2b | 1.9 ± 0.59 |
| GT3a | 2.1 ± 0.66 |
| GT4a | 1.9 ± 0.61 |
| GT5a | 1.4 ± 0.36 |
| GT6a | 2.8 ± 0.67 |
| HCV stable replicons in 40% human plasmaa | |
| GT1a | 64 ± 14 |
| GT1b | 200 ± 54 |
| HIV-1 | >900,000 |
| HBV | >32,000,000 |
a
Both the 0% and 40% human plasma assays also contained 5% fetal bovine serum.
b
The genotype 2a (GT2a) replicon contained M31 in NS5A.
c
Values are means ± standard deviations. EC50, 50% effective concentration.